-
EP4090335
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4090335
| EP4090335 - COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 21.10.2022 Database last updated on 14.05.2024 | |
| Former | The international publication has been made Status updated on 23.07.2021 | ||
| Former | unknown Status updated on 23.03.2021 | Most recent event Tooltip | 29.12.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | [2022/47] | Inventor(s) | 01 /
MENSSEN, Hans Postfach 4002 Basel / CH | 02 /
RINNE, Mikael 250 Massachusetts Avenue Cambridge, MA 02139 / US | 03 /
MALEK, Kamel Postfach 4002 Basel / CH | [2022/47] | Representative(s) | Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | [2022/47] | Application number, filing date | 21711631.8 | 15.01.2021 | [2022/47] | WO2021IB00026 | Priority number, date | US202062962653P | 17.01.2020 Original published format: US 202062962653 P | US202063061001P | 04.08.2020 Original published format: US 202063061001 P | US202063125691P | 15.12.2020 Original published format: US 202063125691 P | [2022/47] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021144657 | Date: | 22.07.2021 | Language: | EN | [2021/29] | Type: | A1 Application with search report | No.: | EP4090335 | Date: | 23.11.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.07.2021 takes the place of the publication of the European patent application. | [2022/47] | Search report(s) | International search report - published on: | EP | 22.07.2021 | Classification | IPC: | A61K31/706, A61K39/395, A61K45/06, A61P35/02 | [2022/47] | CPC: |
A61K31/706 (EP,IL,KR);
A61K39/395 (EP,IL,KR);
C07K16/28 (US);
A61K45/06 (EP,IL,KR);
A61P35/02 (EP,IL,KR,US);
C07K16/2818 (EP,IL,KR);
A61K2039/505 (EP,IL,KR,US);
A61K2039/545 (KR,US);
A61K2300/00 (IL,KR);
| C-Set: |
A61K31/706, A61K2300/00 (EP);
A61K39/395, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/47] | Title | German: | KOMBINATION AUS EINEM TIM-3-INHIBITOR UND EINEM HYPOMETHYLIERUNGSMITTEL ZUR VERWENDUNG BEI DER BEHANDLUNG VON MYELODYSPLASTISCHEM SYNDROM ODER CHRONISCHER MYELOMONOZYTISCHER LEUKÄMIE | [2022/47] | English: | COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA | [2022/47] | French: | POLYTHÉRAPIES COMPRENANT UN INHIBITEUR TIM-3 ET UN AGENT D'HYPOMÉTHYLATION À UTILISER DANS LE TRAITEMENT DU SYNDROME MYÉLODYSPLASIQUE OU DE LA LEUCÉMIE MYÉLOMONOCYTAIRE CHRONIQUE | [2022/47] | Entry into regional phase | 13.07.2022 | National basic fee paid | 13.07.2022 | Designation fee(s) paid | 13.07.2022 | Examination fee paid | Examination procedure | 13.07.2022 | Examination requested [2022/47] | 13.07.2022 | Date on which the examining division has become responsible | 03.03.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 05.09.2022 | Renewal fee patent year 03 | 27.12.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]US2018371093 (BILIC SANELA [US], et al) [X] 1-3,8-15,20,21 * paragraph [0057] *; | [XY]US2019241668 (VAN ROMPAEY LUC [BE]) [X] 1-3,13,14 * paragraphs [0008] , [0 76] , [ 224] - [0225] - [ 232] , [ 253] - [0257] * [Y] 1-44; | [E]WO2021079188 (NOVARTIS AG [CH]) [E] 1-5,13,14,21,24,26 * page 7, line 1 - line 7 *; | [XY] - BORATE UMA ET AL, "Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)", BLOOD, US, vol. 134, no. Supplement_1, doi:10.1182/blood-2019-128178, ISSN 0006-4971, (20191113), pages 570 - 570, URL: https://ashpublications.org/blood/article/134/Supplement_1/570/426380/Phase-Ib-Study-of-the-AntiTIM3-Antibody-MBG453-in, XP055807518 [X] 1-13,15-21 * page 1 * * page 2, paragraph 3 * * page 3, paragraph 1 * [Y] 1-44 DOI: http://dx.doi.org/10.1182/blood-2019-128178 | [Y] - HUNTER ANTHONY M. ET AL, "WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State", BLOOD, US, vol. 134, no. Supplement_1, doi:10.1182/blood-2019-131071, ISSN 0006-4971, (20191113), pages 1717 - 1717, URL: https://ashpublications.org/blood/article/134/Supplement_1/1717/427703/WHODefined-Chronic-Myelomonocytic-Leukemia2-CMML2, XP055807568 [Y] 22-44 * page 2 * DOI: http://dx.doi.org/10.1182/blood-2019-131071 | [A] - Anonymous, "A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1)", ClinicalTrials.gov, INTERNET, (20191104), pages 1 - 9, URL: https://clinicaltrials.gov/ct2/show/NCT04150029, (20210216), XP055776695 [A] 1-44 * page 2 * | [Y] - Zeidan Amer M ET AL, "A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1 | Blood | American Society of Hematology", Blood, (20191113), pages 1 - 7, URL: https://ashpublications.org/blood/article/134/Supplement_1/4259/425609/A-Randomized-Double-Blind-Placebo-Controlled-Phase, (20210525), XP055807234 [Y] 1-44 * page 2 * | [XP] - BRUNNER ANDREW M. ET AL, "Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study", BLOOD, US, vol. 136, no. Supplement 1, doi:10.1182/blood-2020-136855, ISSN 0006-4971, (20201105), pages 1 - 8, URL: https://ashpublications.org/blood/article/136/Supplement%201/1/470443/Efficacy-and-Safety-of-Sabatolimab-MBG453-in, XP055807776 [XP] 1-7,10,13-16,20,21,24,26-28,32,40 * page 1 - page 2 * * page 8; table 1 * DOI: http://dx.doi.org/10.1182/blood-2020-136855 | by applicant | US4433059 | US4444878 | EP0125023 | EP0171496 | EP0173494 | WO8601533 | EP0184187 | GB2188638 | US4816567 | EP0346087 | WO9002809 | EP0388151 | WO9100906 | WO9103493 | WO9110741 | WO9117271 | WO9201047 | WO9203918 | WO9203917 | WO9209690 | WO9215679 | WO9218619 | WO9220791 | EP0519596 | WO9301288 | US5208020 | US5223409 | US5225539 | WO9323537 | US5273743 | WO9404678 | WO9409131 | WO9412625 | WO9509917 | US5475092 | US5534254 | WO9637621 | US5582996 | US5585089 | US5585499 | US5591828 | US5624821 | US5635602 | US5637481 | US5648260 | US5693761 | US5693762 | US5731168 | US5837242 | US5837821 | US5844094 | US5846545 | US5864019 | US5869620 | US5910573 | US5932448 | US5959083 | US5989830 | WO9964460 | US6005079 | WO0006605 | US6239259 | US6294353 | US6333396 | US2002004587 | US2002076406 | US2002103345 | WO02072635 | US6476198 | US6511663 | US2003207346 | US2003211078 | US6670453 | US6743896 | WO2004081051 | US6809185 | US2004219643 | US2004220388 | US2004242847 | US6833441 | US2005003403 | US2005004352 | US2005069552 | US2005079170 | US2005100543 | US2005136049 | US2005136051 | US2005163782 | US2005266425 | WO2006020258 | US2006083747 | US2006120960 | US2006204493 | WO2006105021 | WO2006106905 | US7129330 | WO2006121168 | US2006263367 | US2007004909 | WO2007004606 | US7183076 | US2007087381 | WO2007044887 | US2007128150 | US2007141049 | US2007154901 | WO2007084342 | WO2007095338 | WO2007110205 | US2007274985 | WO2007137760 | US7332582 | US2008050370 | US2008069820 | US2008152645 | US2008171855 | US2008241884 | WO2008119353 | US2008254512 | US2008260738 | WO2008132601 | WO2008143794 | US7488802 | WO2009021754 | WO2009044273 | US7521056 | US7527787 | US7534866 | US2009130106 | WO2009068630 | US2009148905 | US2009155275 | US2009162359 | US2009162360 | US2009175851 | US2009175867 | WO2009089004 | US2009232811 | US2009234105 | WO2009114335 | US2009263392 | US7612181 | US2009274649 | WO2009139888 | WO2010019570 | WO2010027827 | US7695715 | US7812135 | WO2010129304 | WO2011028683 | US7943743 | WO2011066342 | US8008449 | WO2011131746 | US8168179 | US8217149 | WO2012145493 | WO2012175222 | US8354509 | US8388967 | WO2013060867 | WO2013079174 | US8460927 | US8552156 | US8552154 | WO2014022758 | US8686119 | WO2014055897 | US8709424 | WO2014066527 | US8735553 | WO2014100079 | US8779108 | WO2014140180 | US8841418 | US8846628 | WO2014179664 | WO2014194302 | US8907053 | WO2014209804 | US8927697 | WO2015026684 | WO2015031667 | US8993731 | WO2015061668 | US9028823 | WO2015081158 | WO2015085847 | WO2015109124 | US2015210769 | WO2015112800 | WO2015112805 | WO2015117002 | US2015218274 | WO2015116539 | US9102727 | US2015259420 | US9163087 | US9175082 | WO2015181342 | WO2015184099 | US9205148 | WO2015195163 | US2015368349 | WO2015200119 | US9228016 | WO2016000619 | US9244059 | WO2016028672 | WO2016054638 | WO2016057846 | US2016108123 | WO2016071448 | WO2016092419 | WO2016111947 | WO2016144803 | WO2016161270 | US9464139 | US9505839 | WO2016196792 | US2017022284 | WO2017015623 | WO2017019897 | WO2017025610 | US2017073386 | WO2020038355 | - HEANEYGOLDE, N. Engl, J. Med., (19990000), vol. 340, no. 21, pages 1649 - 60 | - GREENBERG et al., Blood, (20120000), vol. 119, no. 16, pages 3734 - 3743 | - PATNAIK et al., Am J Hematol, (20180000), vol. 93, no. 6, pages 824 - 840 | - STEENSMA, Blood Cancer J, (20180000), vol. 8, no. 5, page 47 | - GARCIA-DELGADO et al., Blood, (20190000), vol. 133, no. 10, pages 3932 - 1107 | - ITZYKSON et al., HemaSphere, (20180000), vol. 2, no. 6, page 150 | - JONGEN-LAVRENCIC MGROB THANEKAMP D et al., "Molecular Minimal Residual Disease in Acute Myeloid Leukemia", N Engl J Med, (20180000), vol. 378, no. 13, pages 1189 - 99 | - MONNEY et al., Nature, (20020000), vol. 415, no. 6871, pages 536 - 541 | - SANCHEZ FUEYO et al., Nat Immunol, (20030000), vol. 4, no. 11, pages 1093 - 101 | - ANDERSON et al., Science, (20070000), vol. 318, no. 5853, pages 1141 - 1143 | - KIKUSHIGE et al., Cell Stem Cell, (20100000), vol. 7, no. 6, pages 708 - 717 | - ASAYAMA et al., Oncotarget, (20170000), vol. 8, no. 51, pages 88904 - 88971 | - SAKUISHI et al., J Exp Med., (20100000), vol. 207, no. 10, pages 2187 - 2194 | - NGIOW et al., Cancer Res., (20110000), vol. 71, no. 21, pages 6567 - 6571 | - SAKUISHI et al., Trends Immunol, (20110000), vol. 32, no. 8, pages 345 - 349 | - JING et al., JImmunother Cancer, (20150000), vol. 3, no. 1, page 2 | - ZHANG et al., Leukoc Biol, (20120000), vol. 91, no. 2, pages 189 - 96 | - CHIBA et al., Nat Immunol, (20120000), vol. 13, no. 9, pages 832 - 42 | - DE MINGO PULIDO et al., Cancer Cell, (20180000), vol. 33, no. 1, pages 60 - 74 | - YANG et al., Leukemia, (20140000), vol. 28, no. 6, pages 1280 - 8 | - 0RSKOV et al., Oncotarget, (20150000), vol. 6, no. 11, pages 9612 - 9626 | - CHOU et al., Genes Immun, (20160000), vol. 17, no. 3, pages 179 - 86 | - NEEDLEMANWUNSCH, J. Mol. Biol., (19700000), vol. 48, pages 444 - 453 | - E. MEYERSW. MILLER, CABIOS, (19890000), vol. 4, pages 11 - 17 | - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 10 | - ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 3402 | - HUSE et al., Science, (19890000), vol. 246, pages 1275 - 1281 | - VERHOEYAN et al., Science, (19880000), vol. 239, pages 1534 - 1043 | - HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883 | - GARRAD et al., BiolTechnology, (19910000), vol. 91, pages 1373 - 1 372 | - CHOTHIA, C et al., J. Mol. Biol., vol. 196, pages 901 - 917 | - "Protein Sequence and Structure Analysis of Antibody Variable Domains", Antibody Engineering Lab Manual, Springer-Verlag | - AL-LAZIKANI et al., JMB, (19970000), vol. 273, pages 927 - 948 | - SALEH et al., Cancer Immunol. Immunother, (19900000), vol. 32, pages 180 - 190 | - LOBUGLIO et al., Hybridoma, (19860000), vol. 5, pages 5117 - 5123 | - HAY et al., Hum Antibody Hybridomas, (19920000), vol. 3, pages 81 - 85 | - GRIFFTHS et al., EMBO J, (19930000), vol. 12, pages 725 - 734 | - HAWKINS et al., JMol Biol, (19920000), vol. 226, pages 889 - 896 | - CLACKSON et al., Nature, (19910000), vol. 352, pages 624 - 628 | - GRAM et al., PNAS, (19920000), vol. 89, pages 3576 - 3580 | - HOOGENBOOM et al., Nuc Acid Res, (19910000), vol. 19, pages 4133 - 4137 | - BARBAS et al., PNAS, (19910000), vol. 88, pages 7978 - 7982 | - LONBERG, N. et al., Nature, (19940000), vol. 368, pages 856 - 859 | - GREEN, L.L. et al., Nature Genet, (19940000), vol. 7, pages 13 - 21 | - MORRISON, S.L. et al., Proc. Natl. Acad. Sci. USA, (19940000), vol. 81, pages 6851 - 6855 | - BRUGGEMAN et al., Year Immunol, (19930000), vol. 7, pages 33 - 40 | - TUAILLON et al., PNAS, (19930000), vol. 90, pages 3720 - 3724 | - BRUGGEMAN et al., Eur J Immunol, (19910000), vol. 21, pages 1323 - 1326 | - SUN et al., PNAS, (19870000), vol. 84, pages 3439 - 3443 | - LIU et al., 1, Immunol., (19870000), vol. 139, pages 3521 - 3526 | - NISHIMURA et al., Canc. Res., (19870000), vol. 47, pages 999 - 1005 | - WOOD et al., Nature, (19850000), vol. 314, pages 446 - 449 | - SHAW et al., J. Natl Cancer Inst., (19880000), vol. 80, pages 1553 - 1559 | - MORRISON, S. L., Science, (19850000), vol. 229, pages 1202 - 1207 | - OI et al., BioTechniques, (19860000), vol. 4, page 214 | - JONES et al., Nature, (19860000), vol. 321, pages 552 - 525 | - BEIDLER et al., J. Immunol., (19880000), vol. 141, pages 4053 - 4060 | - COLCHER, D et al., Ann N Y Acad Sci, (19990000), vol. 880, pages 263 - 80 | - REITER, Y, Clin Cancer Res, (19960000), vol. 2, pages 245 - 52 | - LAILLE et al., J Clin Pharmacol, (20140000), vol. 54, no. 6, pages 630 - 639 | - MESIA et al., European Journal of Cancer, (20190000), vol. 123, pages 138 - 154 | - MONTALABAN-BRAVO et al., Current Opinions in Hematology, (20180000), vol. 25, no. 2, pages 146 - 153 | - ELADL et al., Journal of Hematology & Oncology, vol. 13, (20200000), page 96, URL: https://doi.org/10.1186/sl3045-020-00930-1 | - RIETHER et al., Nature Medicine, (20200000), vol. 26, pages 1459 - 1467 | - ZHANG et al., Cell Death and Disease, (20180000), vol. 9, page 439 | - SCHUURHUIS et al., Blood, (20180000), vol. 131, no. 12, pages 1275 - 1291 | - GUPTA et al., Cancer Sensistizing Agents for Chemotherapy, (20190000), pages 125 - 149 | - KIM et al., Cancer Research, (20170000), page 5133 | - FANG et al., Journal for ImmunoTherapy of Cancer, (20190000), vol. 7, page 327 | - PERL et al., N Engl J Med, (20190000), vol. 381, pages 1728 - 1740 | - CORTES et al., The Lancet, (20190000), vol. 20, no. 7, pages 984 - 997 | - ZIMMERMAN et al., Blood, (20130000), vol. 122, no. 22, pages 3607 - 3615 | - HAMID, O et al., New England Journal of Medicine, (20130000), vol. 369, no. 2, pages 134 - 44 | - ROSENBLATT, J et al., J Immunotherapy, (20110000), vol. 34, no. 5, pages 409 - 18 | - MAHNE et al., Cancer Res., (20170000), vol. 77, no. 5, pages 1108 - 1118 | - PONTE J et al., Clinical Immunology;, (20100000), vol. 135, page S96 | - ROSS et al., Cancer Res, (20160000), vol. 76, page 561 | - RAVANDI et al., Blood Adv, (20180000), vol. 2, no. 11, pages 1356 - 1366 | - CAO et al., PLoS One, (20130000), vol. 8, no. 1, page e53834 | - ZHUANG et al., Am J Clin Pathol, (20120000), vol. 137, no. 6, pages 978 - 985 | - KIKUSHIGE et al., Cell Stem Cell, (20101203), vol. 7, no. 6, pages 708 - 17 | - FOURCADE et al., JEM, (20100000), vol. 207, no. 10, page 2175 | WO1986US02269 |